RS58242B1 - Režim doziranja za inhibitore janus kinaze (jak) - Google Patents

Režim doziranja za inhibitore janus kinaze (jak)

Info

Publication number
RS58242B1
RS58242B1 RS20190051A RSP20190051A RS58242B1 RS 58242 B1 RS58242 B1 RS 58242B1 RS 20190051 A RS20190051 A RS 20190051A RS P20190051 A RSP20190051 A RS P20190051A RS 58242 B1 RS58242 B1 RS 58242B1
Authority
RS
Serbia
Prior art keywords
methyl
dose
day
compound
dogs
Prior art date
Application number
RS20190051A
Other languages
English (en)
Serbian (sr)
Inventor
Andrea J Gonzales
Sallie B Cosgrove
Phyllis B Malpas
Michael Rolf Stegemann
Wendy Turner Collard
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS58242(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of RS58242B1 publication Critical patent/RS58242B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
RS20190051A 2012-07-20 2013-07-18 Režim doziranja za inhibitore janus kinaze (jak) RS58242B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors
EP13742573.2A EP2874630B1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (1)

Publication Number Publication Date
RS58242B1 true RS58242B1 (sr) 2019-03-29

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190051A RS58242B1 (sr) 2012-07-20 2013-07-18 Režim doziranja za inhibitore janus kinaze (jak)

Country Status (25)

Country Link
US (1) US9522151B2 (cg-RX-API-DMAC7.html)
EP (1) EP2874630B1 (cg-RX-API-DMAC7.html)
JP (2) JP6022063B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170034949A (cg-RX-API-DMAC7.html)
CN (2) CN104470525A (cg-RX-API-DMAC7.html)
AU (1) AU2013292547B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015000808A2 (cg-RX-API-DMAC7.html)
CA (1) CA2878867C (cg-RX-API-DMAC7.html)
CY (1) CY1121436T1 (cg-RX-API-DMAC7.html)
DK (1) DK2874630T3 (cg-RX-API-DMAC7.html)
ES (1) ES2707627T3 (cg-RX-API-DMAC7.html)
HK (2) HK1209314A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20182088T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042771T2 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00370A (cg-RX-API-DMAC7.html)
LT (1) LT2874630T (cg-RX-API-DMAC7.html)
MX (1) MX360857B (cg-RX-API-DMAC7.html)
NZ (1) NZ703152A (cg-RX-API-DMAC7.html)
PL (1) PL2874630T3 (cg-RX-API-DMAC7.html)
PT (1) PT2874630T (cg-RX-API-DMAC7.html)
RS (1) RS58242B1 (cg-RX-API-DMAC7.html)
SI (1) SI2874630T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900044T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014015107A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500134B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3290421T1 (sl) 2013-02-22 2019-03-29 Pfizer Inc. Kombinacija derivatov pirolo (2,3-D)pirimidina z enim ali več dodatnimi sredstvi za zaviranje z janusom povezane kinaze (JAK)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN120478294A (zh) 2015-10-16 2025-08-15 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2017143014A1 (en) 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
CN107098908B (zh) 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
PT3915989T (pt) * 2019-01-30 2023-10-02 Felicamed Biotechnology Co Ltd Inibidor de jak e método de preparação do mesmo
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
MX2023007150A (es) 2020-12-18 2023-09-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
CA3212256A1 (en) * 2021-03-16 2022-09-22 Juhyun Lee Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
EP4327812A4 (en) * 2021-04-22 2025-01-15 Shenzhen Chipscreen Biosciences Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A SELECTIVE JAK3/JAK1/TBK1 INHIBITOR AND ITS MEDICAL USE
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005852B1 (ru) * 1998-06-19 2005-06-30 Пфайзер Продактс Инк. ПИРРОЛО[2,3-d]ПИРИМИДИНЫ
KR101335843B1 (ko) * 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-d]피리미딘 화합물

Also Published As

Publication number Publication date
CY1121436T1 (el) 2020-05-29
HUE042771T2 (hu) 2019-07-29
KR20170034949A (ko) 2017-03-29
EP2874630A1 (en) 2015-05-27
BR112015000808A2 (pt) 2017-06-27
DK2874630T3 (en) 2019-01-28
IN2015DN00370A (cg-RX-API-DMAC7.html) 2015-06-12
PT2874630T (pt) 2019-01-31
JP2017019816A (ja) 2017-01-26
CN108354938A (zh) 2018-08-03
SI2874630T1 (sl) 2019-04-30
MX360857B (es) 2018-11-20
WO2014015107A1 (en) 2014-01-23
AU2013292547A1 (en) 2015-01-22
EP2874630B1 (en) 2018-12-05
NZ703152A (en) 2016-03-31
SMT201900044T1 (it) 2019-02-28
US20150126535A1 (en) 2015-05-07
HK1252083A1 (zh) 2019-05-17
JP2015522620A (ja) 2015-08-06
HK1209314A1 (en) 2016-04-01
CA2878867C (en) 2018-01-09
ES2707627T3 (es) 2019-04-04
PL2874630T3 (pl) 2019-04-30
KR20150028299A (ko) 2015-03-13
LT2874630T (lt) 2019-02-11
CA2878867A1 (en) 2014-01-23
JP6022063B2 (ja) 2016-11-09
AU2013292547B2 (en) 2017-05-04
MX2015000871A (es) 2015-05-07
CN104470525A (zh) 2015-03-25
US9522151B2 (en) 2016-12-20
HRP20182088T1 (hr) 2019-02-08
ZA201500134B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
RS58242B1 (sr) Režim doziranja za inhibitore janus kinaze (jak)
AU2022252766B2 (en) Treatment of hand eczema
US20240390378A1 (en) Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US20250195476A1 (en) Jak1 pathway inhibitors for the treatment of prurigo nodularis
CN101380317B (zh) 减缓搔痒症的药学组合物
KR20200067859A (ko) Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물
WO2023178001A1 (en) Methods, dosage regimens, and compositions for treating hidradenitis
HK40102338A (en) Treatment of hand eczema
CN119157880A (zh) 一种6-氨基-1H-吡唑并[3,4-d]嘧啶类JAK3激酶抑制剂在治疗特应性皮炎中的应用
KR20240057951A (ko) CaMK2γ 단백질 활성 억제에서 화합물 또는 이의 약학적 유도체의 용도
HK40029681A (en) Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors